Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-Related Kaposi's sarcoma

Drugs

Volumn 53, Issue 3, 1997, Pages 520-538

  Coukell, A J ^a   Spencer, C M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DNA FRAGMENT; DOXORUBICIN; LIPOSOME; MACROGOL; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLINICAL TRIAL; DESQUAMATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; ERYTHEMA; FOOT DISEASE; HAND DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KAPOSI SARCOMA; NAUSEA; NEUTROPENIA; NONHUMAN; QUALITY OF LIFE; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 0030990935     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199753030-00011     Document Type: Article

References (67)

1. 1. C Balmer AW Valley 1993 Basic principles of cancer treatment and cancer chemotherapy JT DiPiro RL Talbert PE Hayes Pharmacotherapy: a pathophysiologic approach 2nd Appleton & Lange Norwalk Connecticut 1879 929 Balmer C, Valley AW. Basic principles of cancer treatment and cancer chemotherapy. In: DiPiro JT, Talbert RL, Hayes PE, et al., editors. Pharmacotherapy: a pathophysiologic approach. 2nd ed. Norwalk Connecticut: Appleton & Lange, 1993: 1879–929
2. 2. SM Sugarman R Perez-Soler 1992 Liposomes in the treatment of malignancy: a clinical perspective Crit Rev Oncol Hematol 12 231 42 1497823 10.1016/1040-8428(92)90056-V 1:STN:280:DyaK38zmtVWksw%3D%3D Sugarman SM, Perez-Soler R. Liposomes in the treatment of malignancy: a clinical perspective. Crit Rev Oncol Hematol 1992; 12: 231–42
3. 3. D Papahadjopoulos TM Allen A Gabizon 1991 Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy Proc Natl Acad Sci USA 88 11460 4 1763060 10.1073/pnas.88.24.11460 1:CAS:528:DyaK38XmslWjsg%3D%3D Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 1991; 88: 11460–4
4. 4. AA Gabizon 1994 Liposomal anthracyclines Hematol Oncol Clin North Am 8 431 50 8040147 1:STN:280:DyaK2czhsVOnsA%3D%3D Gabizon AA. Liposomal anthracyclines. Hematol Oncol Clin North Am 1994 Apr; 8: 431–50
5. 5. A Gabizon M Chemla D Tzemach 1996 Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines J Drug Target 3 5 391 8 8866658 10.3109/10611869608996830 1:CAS:528:DyaK28XhtlKmsbw%3D Gabizon A, Chemla M, Tzemach D, et al. Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. J Drug Target 1996; 3(5): 391–8
6. 6. DD Lasic FJ Martin A Gabizon 1991 Sterically stabilised liposomes: a hypothesis on the molecular origin of the extended circulation times Biochim Biophys Acta 1070 187 92 1751525 10.1016/0005-2736(91)90162-2 1:CAS:528:DyaK38Xisl2kug%3D%3D Lasic DD, Martin FJ, Gabizon A, et al. Sterically stabilised liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta 1991; 1070: 187–92
7. 7. A Gabizon R Isacson E Libson 1994 Clinical studies of liposome-encapsulated doxorubicin Acta Oncol 33 7 779 86 7993646 10.3109/02841869409083948 1:STN:280:DyaK2M%2FosFOqtQ%3D%3D Gabizon A, Isacson R, Libson E, et al. Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol 1994; 33(7): 779–86
8. 8. M Stürzl C Zietz B Eisenburg 1994 Liposomal doxorubicin in the treatment of AIDS-associated Kaposi’s sarcoma: clinical, histological and cell biological evaluation Res Virol 145 261 9 7800953 10.1016/S0923-2516(07)80031-8 Stürzl M, Zietz C, Eisenburg B, et al. Liposomal doxorubicin in the treatment of AIDS-associated Kaposi’s sarcoma: clinical, histological and cell biological evaluation. Res Virol 1994 May–Aug; 145: 261–9
9. 9. SS Williams TR Alosco E Mayhew 1993 Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes Cancer Res 53 3964 7 8358724 1:CAS:528:DyaK2cXhvFE%3D Williams SS, Alosco TR, Mayhew E, et al. Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. Cancer Res 1993 Sep 1; 53: 3964–7
10. 10. J Vaage D Donovan E Mayhew 1993 Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes Cancer 72 3671 5 8252484 10.1002/1097-0142(19931215)72:12<3671::AID-CNCR2820721219>3.0.CO;2-U 1:CAS:528:DyaK2cXktVSgsbs%3D Vaage J, Donovan D, Mayhew E. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer 1993 Dec 15; 72: 3671–5
11. 11. J Vaage E Barberá-Guillem R Abra 1993 Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts Cancer 73 1478 784 10.1002/1097-0142(19940301)73:5<1478::AID-CNCR2820730526>3.0.CO;2-1 Vaage J, Barberá-Guillem E, Abra R, et al. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 1993; 73: 1478–784
12. 12. Logan DM, Fillion LG, Gaudreault R, et al. The effect of daunorubicin (Dauno) or doxorubicin (Doxo) on epidemic Kaposi’s sarcoma (EKS) derived cell cultures [abstract no. W.A.1030]. VIIth International Conference on AIDS, 1991 Jun 16–21, Florence, Italy: 99
13. 13. W Budach V Budach M Stuschke 1994 Efficacy of ifosfamide, dacarbazine, doxorubicin and cisplatin in human sarcoma xenografts Br J Cancer 70 29 34 8018537 10.1038/bjc.1994.245 1:CAS:528:DyaK2cXmsVGgsL4%3D Budach W, Budach V, Stuschke M, et al. Efficacy of ifosfamide, dacarbazine, doxorubicin and cisplatin in human sarcoma xenografts. Br J Cancer 1994; 70: 29–34
14. 14. MA Amantea A Forrest C DuMond 1995 Population PK and PD of liposomal doxorubicin (LD) in HIV-infected patients (PTS) with Kaposi’s sarcoma (KS) [abstract no, PI-82A] Clin Pharmacol Ther 57 155 Amantea MA, Forrest A, DuMond C, et al. Population PK and PD of liposomal doxorubicin (LD) in HIV-infected patients (PTS) with Kaposi’s sarcoma (KS) [abstract no, PI-82A]. Clin Pharmacol Ther 1995 Feb; 57: 155
15. 15. DW Northfelt FJ Martin P Working 1996 Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi’s sarcoma J Clin Pharmacol 36 55 63 8932544 1:CAS:528:DyaK28Xhs1egt7s%3D Northfelt DW, Martin FJ, Working P, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi’s sarcoma. J Clin Pharmacol 1996 Jan; 36: 55–63
16. 16. DW Northfelt FJ Martin LD Kaplan 1993 Pharmacokinetics (PK), tumor localization (TL), and safety of Doxil™ (liposomal doxorubicin) in AIDS patients with Kaposi’s sarcoma (AIDS-KS) [abstract no.8] Proc Am Soc Clin Oncol 12 51 Northfelt DW, Martin FJ, Kaplan LD, et al. Pharmacokinetics (PK), tumor localization (TL), and safety of Doxil™ (liposomal doxorubicin) in AIDS patients with Kaposi’s sarcoma (AIDS-KS) [abstract no.8]. Proc Am Soc Clin Oncol 1993 Mar; 12: 51
17. 17. A Gabizon R Catane B Uziely 1994 Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes Cancer Res 54 987 92 8313389 1:CAS:528:DyaK2cXhslegs70%3D Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994 Feb 15; 54: 987–92
18. 18. RF Greene JM Collins JF Jenkins 1983 Plasma pharmacokinetics of Adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols Cancer Res 43 3417 21 6850648 1:STN:280:DyaL3s3gs1Kgtw%3D%3D Greene RF, Collins JM, Jenkins JF, et al. Plasma pharmacokinetics of Adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Res 1983; 43: 3417–21
19. 19. PAJ Speth QGCM Hoesel van C Haanen 1988 Clinical pharmacokinetics of doxorubicin Clin Pharmacokinet 15 15 31 3042244 10.2165/00003088-198815010-00002 1:STN:280:DyaL1c3psFKjtQ%3D%3D Speth PAJ, van Hoesel QGCM, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 1988; 15: 15–31
20. 20. AA Gabizon Y Barenholz M Bialer 1993 Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs Pharm Res 10 703 8 8321835 10.1023/A:1018907715905 1:CAS:528:DyaK3sXkvVSjt7c%3D Gabizon AA, Barenholz Y, Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm Res 1993 May; 10: 703–8
21. 21. KJ Harrington CSR Gooden S Mohammedtaghi 1996 Biodistribution and pharmacokinetics of In-111-labeled Stealth® liposomes in patients with solid tumours [abstract no. 1511] Proc Am Soc Clin Oncol 15 477 Harrington KJ, Gooden CSR, Mohammedtaghi S, et al. Biodistribution and pharmacokinetics of In-111-labeled Stealth® liposomes in patients with solid tumours [abstract no. 1511]. Proc Am Soc Clin Oncol 1996; 15: 477
22. 22. TM Allen 1994 Long-circulating (sterically stabilized) liposomes for targeted drug delivery Trends Pharmacol Sci 15 215 20 7940982 10.1016/0165-6147(94)90314-X 1:CAS:528:DyaK2cXlsVWhu7c%3D Allen TM. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci 1994 Jul; 15: 215–20
23. 23. SK Huang K-D Lee K Hong 1992 Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice Cancer Res 52 5135 43 1394121 1:CAS:528:DyaK38Xmtl2ltLo%3D Huang SK, Lee K-D, Hong K, et al. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res 1992; 52: 5135–43
24. 24. C-Y Wang AL Schroeter WPD Su 1995 Acquired immunodeficiency syndrome-related Kaposi’s sarcoma Mayo Clin Proc 70 869 79 7643641 1:STN:280:DyaK2MzntFersQ%3D%3D Wang C-YE, Schroeter AL, Su WPD. Acquired immunodeficiency syndrome-related Kaposi’s sarcoma. Mayo Clin Proc 1995 Sep; 70: 869–79
25. 25. DW Northfelt 1994 Stealth® liposomal doxorubicin (SLD) delivers more doxorubicin (DOX) to AIDS-Kaposi’s sarcoma (AIDS-KS) lesions than to normal skin [abstract no. 5] Proc Am Soc Clin Oncol 13 51 Northfelt DW Stealth® liposomal doxorubicin (SLD) delivers more doxorubicin (DOX) to AIDS-Kaposi’s sarcoma (AIDS-KS) lesions than to normal skin [abstract no. 5]. Proc Am Soc Clin Oncol 1994 Mar; 13: 51
26. 26. J Robert P Vrignaud T Nguyen-Ngoc 1985 Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer Cancer Treat Rep 69 6 633 40 3893693 1:STN:280:DyaL2M3lsVGiuw%3D%3D Robert J, Vrignaud P, Nguyen-Ngoc T, et al. Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer. Cancer Treat Rep 1985; 69(6): 633–40
27. 27. A Rahman J Treat J-K Roh 1990 A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin J Clin Oncol 8 1093 100 2348224 1:STN:280:DyaK3c3ntV2juw%3D%3D Rahman A, Treat J, Roh J-K, et al. A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol 1990 Jun; 8: 1093–100
28. 28. JW Cowens PJ Creaven WR Greco 1993 Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes) Cancer Res 53 2796 802 8504422 1:STN:280:DyaK3s3nvVKkuw%3D%3D Cowens JW, Creaven PJ, Greco WR, et al. Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res 1993; 53: 2796–802
29. 29. A Gabizon R Chisin S Amselem 1991 Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin Br J Cancer 64 1125 32 1764376 10.1038/bjc.1991.476 1:STN:280:DyaK387htVWrtw%3D%3D Gabizon A, Chisin R, Amselem S, et al. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br J Cancer 1991 Dec; 64: 1125–32
30. 30. AP Venook M Amantea E Bonnern 1996 Pegylated liposome-encapsulated doxorubicin (Doxil®) in patients with hepatocellular carcinoma (HCC) [abstract no. 1494] Proc Am Soc Clin Oncol 15 473 Venook AP, Amantea M, Bonnern E, et al. Pegylated liposome-encapsulated doxorubicin (Doxil®) in patients with hepatocellular carcinoma (HCC) [abstract no. 1494]. Proc Am Soc Clin Oncol 1996; 15: 473
31. 31. B Uziely S Jeffers R Isacson 1995 Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies J Clin Oncol 13 1777 85 7602367 1:STN:280:DyaK2MzisFyqug%3D%3D Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995 Jul; 13: 1777–85
32. 32. F Muggia J Hainsworth S Jeffers 1996 Liposomal doxorubicin (Doxil) is active against refractory ovarian cancer [abstract no. 781] Proc Am Soc Clin Oncol 15 287 Muggia F, Hainsworth J, Jeffers S, et al. Liposomal doxorubicin (Doxil) is active against refractory ovarian cancer [abstract no. 781]. Proc Am Soc Clin Oncol 1996; 15: 287
33. 33. M Ranson K O’Byrne J Carmichael 1996 Phase II dose-finding trial of DOX-SL™ (Stealth®) liposomal doxorubicin HCL) in the treatment of advanced breast cancer [abstract no. 161] Proc Am Soc Clin Oncol 15 124 Ranson M, O’Byrne K, Carmichael J, et al. Phase II dose-finding trial of DOX-SL™ (Stealth®) liposomal doxorubicin HCL) in the treatment of advanced breast cancer [abstract no. 161]. Proc Am Soc Clin Oncol 1996; 15: 124
34. 34. HM Ockenfels NH Brockmeyer U Hengge 1996 Cutaneous angiosarcoma: a novel therapy with liposomal doxorubicin? J Eur Acad Dermatol Venereol 6 71 5 10.1111/j.1468-3083.1996.tb00138.x Ockenfels HM, Brockmeyer NH, Hengge U, et al. Cutaneous angiosarcoma: a novel therapy with liposomal doxorubicin? J Eur Acad Dermatol Venereol 1996; 6: 71–5
35. 35. F-D Goebel D Goldstein M Goos 1996 Efficacy and safety of Stealth® liposomal doxorubicin in AIDS-related Kaposi’s sarcoma Br J Cancer 73 989 94 8611437 10.1038/bjc.1996.193 1:CAS:528:DyaK28XjtFKhu78%3D Goebel F-D, Goldstein D, Goos M, et al. Efficacy and safety of Stealth® liposomal doxorubicin in AIDS-related Kaposi’s sarcoma. Br J Cancer 1996 Apr; 73: 989–94
36. 36. JR Bogner U Kronawitter B Rolinski 1994 Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma J Acquir Immune Defic Syndr 7 463 8 8158540 1:STN:280:DyaK2c3htVeksw%3D%3D Bogner JR, Kronawitter U, Rolinski B, et al. Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma. J Acquir Immune Defic Syndr 1994 May; 7: 463–8
37. 37. MJ Boyle NE Marshall GM Dolan 1993 A phase II study of Stealth liposomal doxorubicin HCL (S-DXR) in HIV-associated Kaposi’s sarcoma [abstract no. PO-B12-1570] 9th International Conference on AIDS 1 397 Boyle MJ, Marshall NE, Dolan GM, et al. A phase II study of Stealth liposomal doxorubicin HCL (S-DXR) in HIV-associated Kaposi’s sarcoma [abstract no. PO-B12-1570]. 9th International Conference on AIDS; 1993 Jun 6–11; Berlin, Germany; vol. 1: 397
38. 38. UR Hengge NH Brockmeyer M Baumann 1993 Liposomal doxorubicin in AIDS-related Kaposi’s sarcoma [letter] Lancet 342 497 8102452 10.1016/0140-6736(93)91624-U 1:STN:280:DyaK3szltl2rug%3D%3D Hengge UR, Brockmeyer NH, Baumann M, et al. Liposomal doxorubicin in AIDS-related Kaposi’s sarcoma [letter]. Lancet 1993 Aug 21; 342: 497
39. 39. J Thommes D Northfelt A Rios 1994 Open-label trial of Stealth® liposomal doxorubicin (D-SL) in the treatment of moderate to severe AIDS-related Kaposi’s sarcoma (AIDS-KS) [abstract no. 24] Proc Am Soc Clin Oncol 13 55 Thommes J, Northfelt D, Rios A, et al. Open-label trial of Stealth® liposomal doxorubicin (D-SL) in the treatment of moderate to severe AIDS-related Kaposi’s sarcoma (AIDS-KS) [abstract no. 24]. Proc Am Soc Clin Oncol 1994 Mar; 13: 55
40. 40. DW Northfelt B Dezube B Miller 1995 Randomized comparative trial of Doxil vs. Adriamycin, bleomycin, and vincristine (ABV) in the treatment of severe AIDS-related Kaposi’s sarcoma (AIDS-KS) [abstract no. 1515] Blood 86 10 382 Northfelt DW, Dezube B, Miller B, et al. Randomized comparative trial of Doxil vs. Adriamycin, bleomycin, and vincristine (ABV) in the treatment of severe AIDS-related Kaposi’s sarcoma (AIDS-KS) [abstract no. 1515]. Blood 1995; 86(10) Suppl. 1: 382a
41. 41. Stewart JSW, Jablonowski H, Goebel FD, et al. A randomised comparative trial of DOXIL® versus bleomycin and vincristine (BV) in the treatment of AIDS-related Kaposi’s sarcoma. SEQUUS Pharmaceuticals (London), 1996 (Data on file)
42. 42. M Harrison A Denton D Tomlinson 1995 AIDS related Kaposi’s sarcoma: comparison of liposomal entrapped doxorubicin (LED) with bleomycin and vincristine (BV) [abstract no. O35] Br J Cancer 72 25 12 Harrison M, Denton A, Tomlinson D, et al. AIDS related Kaposi’s sarcoma: comparison of liposomal entrapped doxorubicin (LED) with bleomycin and vincristine (BV) [abstract no. O35]. Br J Cancer 1995 Jul; 72 Suppl. 25: 12
43. 43. M Harrison D Tomlinson S Stewart 1995 Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi’s sarcoma J Clin Oncol 13 4 914 20 7707119 1:STN:280:DyaK2M3it1eiuw%3D%3D Harrison M, Tomlinson D, Stewart S. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi’s sarcoma. J Clin Oncol 1995 Apr; 13(4): 914–20
44. 44. H Jablonowski D Boden D Häussinger 1996 Long term use of DOX-SL™ (Stealth® liposomal doxorubicin HC1) in the treatment of moderate to severe AIDS-related Kaposi’s sarcoma [abstract no. 842] Proc Am Soc Clin Oncol 15 303 Jablonowski H, Boden D, Häussinger D. Long term use of DOX-SL™ (Stealth® liposomal doxorubicin HC1) in the treatment of moderate to severe AIDS-related Kaposi’s sarcoma [abstract no. 842]. Proc Am Soc Clin Oncol 1996; 15: 303
45. 45. SE Krown C Metroka JC Wernz 1989 Kaposi’s sarcoma in the aquired immune deficiency sydrome: a proposal for uniform evaluation, response, and staging criteria J Clin Oncol 7 9 1201 7 2671281 1:STN:280:DyaL1MzmtFGmsQ%3D%3D Krown SE, Metroka C, Wernz JC, et al. Kaposi’s sarcoma in the aquired immune deficiency sydrome: a proposal for uniform evaluation, response, and staging criteria. J Clin Oncol 1989; 7(9): 1201–7
46. 46. SE Krown M Testa J Huang 1996 Validation of the AIDS Clinical Trials Group (ACTG) staging classification for AIDS-associated Kaposi’s sarcoma (AIDS/KS) [abstract no. 844] Proc Am Soc Clin Oncol 15 303 Krown SE, Testa M, Huang J. Validation of the AIDS Clinical Trials Group (ACTG) staging classification for AIDS-associated Kaposi’s sarcoma (AIDS/KS) [abstract no. 844]. Proc Am Soc Clin Oncol 1996; 15: 303
47. 47. Esser S, Bleil M, Reimann G, et al. Long term treatment with liposomal doxorubicin in patients with AIDS-related Kaposi’s sarcoma [abstract no. Th.A.4077]. 11th International Conference on AIDS; 1996 Jul 7–12: Vancouver, Canada. Transcontinental Printing, 1996: 266
48. 48. G Rizzardini GM Vigevani L Cremoni 1995 Liposomal doxorubicin (LD) or bleomycin plus vincristine (BV) in epidemic Kaposi’s sarcoma (KS) [abstract no. 2173] Can J Infect Dis 6 C 371C Rizzardini G, Vigevani GM, Cremoni L, et al. Liposomal doxorubicin (LD) or bleomycin plus vincristine (BV) in epidemic Kaposi’s sarcoma (KS) [abstract no. 2173]. Can J Infect Dis 1995 Jul; 6 Suppl. C: 371C
49. 49. MD Volm JH Roenn Von 1995 Treatment strategies for epidemic Kaposi’s sarcoma Curr Opin Oncol 7 429 36 8541388 10.1097/00001622-199509000-00008 1:STN:280:DyaK28%2Fns1akug%3D%3D Volm MD, Von Roenn JH. Treatment strategies for epidemic Kaposi’s sarcoma. Curr Opin Oncol 1995 Sep; 7: 429–36
50. 50. C Bergin A O’Leary C McCreary 1995 Treatment of Kaposi’s sarcoma with liposomal doxorubicin Am J Health System Pharm 52 2001 4 1:CAS:528:DyaK2MXos1Clsrc%3D Bergin C, O’Leary A, McCreary C, et al. Treatment of Kaposi’s sarcoma with liposomal doxorubicin. Am J Health System Pharm 1995 Sep 15; 52: 2001–4
51. 51. ND James RJ Coker D Tomlinson 1994 Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi’s sarcoma in AIDS Clin Oncol 6 294 6 10.1016/S0936-6555(05)80269-9 1:STN:280:DyaK2M7islGgsg%3D%3D James ND, Coker RJ, Tomlinson D, et al. Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi’s sarcoma in AIDS. Clin Oncol 1994; 6: 294–6
52. 52. F Milazzo G Rizzardini A Capetti 1994 Efficacy and toxicity of Doxil (Stealth liposomal doxorubicin HCL) in moderate/severe epidemic Kaposi’s sarcoma [abstract] AIDS 8 4 S46 10.1097/00002030-199411004-00180 Milazzo F, Rizzardini G, Capetti A, et al. Efficacy and toxicity of Doxil (Stealth liposomal doxorubicin HCL) in moderate/severe epidemic Kaposi’s sarcoma [abstract]. AIDS 1994 Nov; 8 Suppl. 4: S46
53. 53. JK Simpson RF Miller MF Spittle 1993 Liposomal doxorubicin for treatment of AIDS-related Kaposi’s sarcoma Clin Oncol 5 372 4 10.1016/S0936-6555(05)80089-5 1:STN:280:DyaK2c7jslKgtA%3D%3D Simpson JK, Miller RF, Spittle MF. Liposomal doxorubicin for treatment of AIDS-related Kaposi’s sarcoma. Clin Oncol 1993; 5: 372–4
54. 54. D Wagner WV Kern P Kern 1994 Liposomal doxorubicin in AIDS-related Kaposi’s sarcoma: long-term experiences Clin Investig 72 417 23 7950152 1:STN:280:DyaK2M%2FjslCksA%3D%3D Wagner D, Kern WV, Kern P. Liposomal doxorubicin in AIDS-related Kaposi’s sarcoma: long-term experiences. Clin Investig 1994 Jun; 72: 417–23
55. 55. F-D Goebel M Gruenaug JR Bogner 1996 Survival times of patients with AIDS-related Kaposi’s sarcoma with pulmonary involvement using liposomal doxorubicin [abstract no. 860] Proc Am Soc Clin Oncol 15 307 Goebel F-D, Gruenaug M, Bogner JR. Survival times of patients with AIDS-related Kaposi’s sarcoma with pulmonary involvement using liposomal doxorubicin [abstract no. 860]. Proc Am Soc Clin Oncol 1996; 15: 307
56. 56. Dezube BJ. Safety assessment: Doxil® (doxorubicin HCl liposome injection) in refractory AIDS-related Kaposi’s sarcoma. Doxil® Clinical Series.Vol. 1, No. 2; SEQUUS Pharmaceuticals, Inc., Menlo Park, California, 1996.
57. 57. PS Gill M Rarick JA McCutchan 1991 Systemic treatment of AIDS-related Kaposi’s sarcoma: results of a randomized trial Am J Med 90 427 33 1707230 1:STN:280:DyaK3M7ovFWrsQ%3D%3D Gill PS, Rarick M, McCutchan JA, et al. Systemic treatment of AIDS-related Kaposi’s sarcoma: results of a randomized trial. Am J Med 1991; 90: 427–33
58. 58. G Berry M Billingham E Alderman 1996 Reduced cardiotoxicity of DOXIL (pegylated liposomal doxorubicin) in AIDS Kaposi’s sarcoma patients compared to a matched control group of cancer patients given doxorubicin [abstract no. 843] Proc Am Soc Clin Oncol 15 303 Berry G, Billingham M, Alderman E, et al. Reduced cardiotoxicity of DOXIL (pegylated liposomal doxorubicin) in AIDS Kaposi’s sarcoma patients compared to a matched control group of cancer patients given doxorubicin [abstract no. 843]. Proc Am Soc Clin Oncol 1996; 15: 303
59. 59. S Madhavan DW Northfelt 1995 Lack of vesicant injury following extravasation of liposomal doxorubicin [letter] J Natl Cancer Inst 87 1556 7 7563191 10.1093/jnci/87.20.1556 1:STN:280:DyaK28%2FgtlOisA%3D%3D Madhavan S, Northfelt DW. Lack of vesicant injury following extravasation of liposomal doxorubicin [letter]. J Natl Cancer Inst 1995 Oct 18; 87: 1556–7
60. 60. S Madhavan DW Northfelt 1996 Lack of vesicant injury following extravasation of liposomal doxorubicin [abstract] Breast Cancer Res Treat 37 77 10.1007/BF01806634 Madhavan S, Northfelt DW. Lack of vesicant injury following extravasation of liposomal doxorubicin [abstract]. Breast Cancer Res Treat 1996; 37 Suppl.: 77
61. 61. UR Hengge NH Brockmeyer R Rasshofer 1993 Fatal hepatic failure with liposomal doxorubicin [letter] Lancet 341 383 4 8094161 10.1016/0140-6736(93)90198-P 1:STN:280:DyaK3s7ls1Cqtg%3D%3D Hengge UR, Brockmeyer NH, Rasshofer R, et al. Fatal hepatic failure with liposomal doxorubicin [letter]. Lancet 1993 Feb 6; 341: 383–4
62. 62. RJ Coker ND James JSW Stewart 1993 Hepatic toxicity of liposomal encapsulated doxorubicin [letter] Lancet 341 756 8095649 10.1016/0140-6736(93)90525-L 1:STN:280:DyaK3s7ps1eltQ%3D%3D Coker RJ, James ND, Stewart JSW. Hepatic toxicity of liposomal encapsulated doxorubicin [letter]. Lancet 1993 Mar 20; 341: 756 au63._SEQUUS Pharmaceuticals Inc. Doxil® prescribing information. Menlo Park, California, USA, 1995.
63. 64. M Harrison KJ Harrington JSW Stewart 1995 Liposomal chemotherapy for AIDS-related Kaposi’s sarcoma Expert Opin Invest Drug 4 1197 203 10.1517/13543784.4.12.1197 1:CAS:528:DyaK28XnsVSrug%3D%3D Harrison M, Harrington KJ, Stewart JSW. Liposomal chemotherapy for AIDS-related Kaposi’s sarcoma. Expert Opin Invest Drug 1995 Dec; 4: 1197–203
64. 65. RC Lilenbaum L Ratner 1994 Systemic treatment of Kaposi’s sarcoma: current status and future directions AIDS 8 141 51 7519018 10.1097/00002030-199402000-00001 1:STN:280:DyaK2czhvVWqtQ%3D%3D Lilenbaum RC, Ratner L. Systemic treatment of Kaposi’s sarcoma: current status and future directions. AIDS 1994 Feb; 8: 141–51
65. 66. S-J Gao L Kingsley DR Hoover 1996 Seroconversion to antibodies against Kaposi’s sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi’s sarcoma N Engl J Med 335 233 41 8657239 10.1056/NEJM199607253350403 1:STN:280:DyaK283ms1ertw%3D%3D Gao S-J, Kingsley L, Hoover DR, et al. Seroconversion to antibodies against Kaposi’s sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi’s sarcoma. N Engl J Med 1996 Jul 25; 335: 233–41
66. 67. CA Presant M Scolaro P Kennedy 1993 Liposomal daunorubicin treatment of HIV-associated Kaposi’s sarcoma Lancet 341 1242 3 8098393 10.1016/0140-6736(93)91147-E 1:STN:280:DyaK3s3mtFSrtA%3D%3D Presant CA, Scolaro M, Kennedy P, et al. Liposomal daunorubicin treatment of HIV-associated Kaposi’s sarcoma. Lancet 1993; 341: 1242–3
67. 68. DW Northfelt 1994 Treatment of Kaposi’s sarcoma: current guidelines and future perspectives Drugs 48 569 82 7528130 10.2165/00003495-199448040-00006 1:STN:280:DyaK2M%2FpsVKgtA%3D%3D Northfelt DW. Treatment of Kaposi’s sarcoma: current guidelines and future perspectives. Drugs 1994 Oct; 48: 569–82